FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids

Loading...
Loading...

The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's CTXR Halo-Lido to treat hemorrhoids. The Company anticipates initiating a Phase 2b study in 1H of 2022.

  • Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine intended to provide symptomatic relief to individuals suffering from hemorrhoids. 
  • Hemorrhoid is a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding. 
  • The Phase 2b study is designed as a multi-center, randomized, dose-ranging, double-blind, parallel-group comparison. 
  • Five cohorts of adults with a clinical diagnosis of symptomatic Goligher's classification Grade II or Grade III hemorrhoids will be dosed. 
  • Approximately 60 subjects per cohort are expected to be enrolled, for a total of 300 subjects. The primary endpoint of the study will be the reduction in hemorrhoidal symptoms. 
  • The secondary endpoint will reduce hemorrhoidal bother (such as bowel movement interference and pressure) following treatment.
  • Patients will utilize Citius's ePRO distributed to subjects using a smartphone app to record information and assessments.
  • Price Action: CTXR shares are trading 5.19% higher at $1.62 during the market session on the last check Tuesday.
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...